Research Banner Thierry

About us

The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research centre at the University of Oxford supported by Parkinson’s UK with funds from The Monument Trust, one of the Sainsbury Family Charitable Trusts.

Established in February 2010, the Oxford Parkinson’s Disease Centre (OPDC) brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.

Our world-class research centre was formed to understand the earliest events in the development of Parkinson’s and create animal models with greater relevance to the disease, ultimately with a view to identifying the changes which occur before the symptoms become apparent.

Our programme targets the molecular pathways to Parkinson’s in order to:

  1. Understand the progression of Parkinson’s
  2. Predict the onset of Parkinson’s
  3. Identify potential drug targets for Parkinson’s
  4. Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
  • Watch the video below to learn more about OPDC's research

 

Selected Publications

News

Mission Therapeutics and OPDC PI Richard Wade-Martins awarded research grant from the Michael J. Fox Foundation

Mission Therapeutics and OPDC PI Richard Wade-Martins awarded research grant from the Michael J. Fox Foundation

Posted 11/04/2017

Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). This research grant, announced on World Parkinson’s day, will support the testing of Mission Therapeutics’ potent ...


OPDC Investigator heads up new consortium to investigate aggregated proteins in Alzheimer’s and Parkinson’s

OPDC Investigator heads up new consortium to investigate aggregated proteins in Alzheimer’s and Parkinson’s

Posted 10/04/2017

The Innovative Medicines Initiative (IMI) launched IMPRiND in March 2017, an innovative research project that is devoted to investigating whether mechanisms of propagation of aggregated proteins between cells could enable novel therapeutic approaches in Alzheimer’s and Parkinson’s. Alzheimer’s and Parkinson’s are age-related neurodegenerative disorders without cure. They are characterised by the progressive loss of brain cells often along ...


Monique from our OPDC cohort on her experiences

Monique from our OPDC cohort on her experiences

Posted 09/02/2017

Here OPDC participant talks about why being part of such a vast project is very exciting.

"At a time in my life when I cannot do what I used to, taking part in health research gives me a sense of purpose and of still belonging to society and playing my part. It keeps my brain going and gives me hope that one day other people like us, their families and friends will benefit from the results. I have no doubt participating in these studies has helped my confidence"Click here to sign up to the OPDC News Mailing list

Seminars/Events

Beate Ritz - 25 April 2017

Beate Ritz - 25 April 2017

Posted 30/09/2016

Professor Beate Ritz joined the faculty of the School of Public Health at UCLA in 1995 and is currently Professor and Vice Chair of the Epidemiology Department and holds co-appointments in the Environmental Health department at the UCLA School of Public Health and in Neurology, UCLA School of Medicine. Her research focuses on the health effects of occupational and environmental toxins such as pesticides, ionizing radiation, and air pollution on ...

Hilal Lashuel 16 May 2017

Hilal Lashuel 16 May 2017

Posted 30/09/2016

Professor Hilal Lashuel is an Associate Professor of Life Sciences and Director of the Laboratory of Chemical Biology of Neurodegeneration, Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne, Switzerland. Research efforts in Lashuel’s laboratory cover the following topics: (1) Elucidating the structural basis of amyloid-associated toxicity in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases; (2) ...

Med Sci
OUH TrustBRC logoNIHR